Immunome, Inc. (NASDAQ:IMNM) Receives $30.09 Average PT from Brokerages

by · The Markets Daily

Shares of Immunome, Inc. (NASDAQ:IMNM – Get Free Report) have earned an average rating of “Moderate Buy” from the eleven analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $30.0909.

Several equities analysts have recently commented on IMNM shares. Guggenheim upped their price target on shares of Immunome from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Lake Street Capital upped their target price on shares of Immunome from $22.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Leerink Partners set a $40.00 price target on shares of Immunome in a research note on Monday, December 15th. Evercore ISI boosted their price objective on Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. Finally, Wedbush reissued an “outperform” rating and issued a $21.00 price objective on shares of Immunome in a report on Friday, November 7th.

Read Our Latest Stock Analysis on Immunome

Insider Transactions at Immunome

In related news, insider Philip Tsai bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was purchased at an average price of $20.49 per share, for a total transaction of $204,900.00. Following the transaction, the insider directly owned 43,300 shares of the company’s stock, valued at approximately $887,217. This represents a 30.03% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Isaac Barchas sold 383,200 shares of the business’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the sale, the director owned 2,031,181 shares in the company, valued at $44,157,874.94. This trade represents a 15.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders acquired 68,518 shares of company stock valued at $1,453,958. 7.69% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Invesco Ltd. raised its holdings in Immunome by 6.4% during the first quarter. Invesco Ltd. now owns 28,379 shares of the company’s stock worth $191,000 after purchasing an additional 1,718 shares in the last quarter. MetLife Investment Management LLC raised its stake in shares of Immunome by 19.1% in the 1st quarter. MetLife Investment Management LLC now owns 42,411 shares of the company’s stock worth $285,000 after buying an additional 6,792 shares in the last quarter. Corebridge Financial Inc. raised its stake in shares of Immunome by 35.9% in the 1st quarter. Corebridge Financial Inc. now owns 34,735 shares of the company’s stock worth $234,000 after buying an additional 9,179 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Immunome by 55.0% in the first quarter. Adage Capital Partners GP L.L.C. now owns 775,000 shares of the company’s stock valued at $5,216,000 after buying an additional 275,000 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Immunome by 44.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock valued at $316,000 after buying an additional 14,398 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Trading Up 3.0%

Shares of Immunome stock opened at $21.07 on Monday. The business’s 50 day simple moving average is $19.27 and its 200-day simple moving average is $13.93. The stock has a market capitalization of $1.93 billion, a price-to-earnings ratio of -7.14 and a beta of 2.22. Immunome has a twelve month low of $5.15 and a twelve month high of $25.30.

Immunome (NASDAQ:IMNM – Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. Sell-side analysts predict that Immunome will post -2.21 earnings per share for the current year.

About Immunome

(Get Free Report)

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

Featured Articles